- Product NameS49076 HCl
- Brief DescriptionInhibitors
- Purification98.00%
- Biological ActivityS49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3. S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstream signaling in vitro and in vivo. In cell models, S49076 inhibited the proliferation of MET- and FGFR2-dependent gastric cancer cells, blocked MET-driven migration of lung carcinoma cells, and inhibited colony formation of hepatocarcinoma cells expressing FGFR1/2 and AXL. In tumor xenograft models, a good pharmacokinetic/pharmacodynamic relationship for MET and FGFR2 inhibition following oral administration of S49076 was established and correlated well with impact on tumor growth. MET, AXL, and the FGFRs have all been implicated in resistance to VEGF/VEGFR inhibitors such as bevacizumab. A phase I study with S-49076 is currently underway in patients with advanced solid tumors.
- Target Namec-Met/HGFR inhibitor; FGFR inhibitor; TAM Receptor inhibitor
- CAS No. 1265966-31-1
- Calculated MW 439.852
- Formulation C22H18ClN3O5
- Storage 3 years -20˚C powder;2 years -80˚C in solvent;
